Silica-Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment

Chem Rec. 2021 Jun;21(6):1535-1568. doi: 10.1002/tcr.202000104. Epub 2020 Dec 15.

Abstract

Prostate cancer (PCa) is one of the most commonly diagnosed cancers and is the fifth common cause of cancer-related mortality in men. Current methods for PCa treatment are insufficient owing to the challenges related to the non-specificity, instability and side effects caused by the drugs and therapy agents. These drawbacks can be mitigated by the design of a suitable drug delivery system that can ensure targeted delivery and minimise side effects. Silica based nanoparticles (SBNPs) have emerged as one of the most versatile materials for drug delivery due to their tunable porosities, high surface area and tremendous capacity to load various sizes and chemistry of drugs. This review gives a brief overview of the diagnosis and current treatment strategies for PCa outlining their existing challenges. It critically analyzes the design, development and application of pure, modified and hybrid SBNPs based drug delivery systems in the treatment of PCa, their advantages and limitations.

Keywords: Drug delivery; drug targeting; mesoporous silica; nanomaterials; prostate cancer.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • Drug Carriers / chemistry
  • Drug Delivery Systems*
  • Humans
  • Male
  • Nanoparticles / chemistry*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Silicon Dioxide / chemistry*

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Silicon Dioxide